IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...
IGM Biosciences has pivoted from cancer therapeutics to autoimmune diseases despite setbacks, showing a 25% stock increase since last October. Click for more on IGMS.
Investor's Business Daily on MSN2mon
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite MakeoverThe company is now pivoting to autoimmune diseases, prioritizing a drug called imvotamab. IGM Biosciences is developing ...
BMO Capital initiated coverage of IGM Biosciences (IGMS) with an Outperform rating and $21 price target IGM is a clinical-stage biotechnology ...
M.D., Chief Executive Officer of IGM Biosciences. "Our near-term focus for imvotamab remains generating robust initial data sets in rheumatoid arthritis, systemic lupus erythematosus and myositis.
Quest Partners LLC lessened its stake in IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) by 86.2% in the 3rd quarter, ...
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback